Drug Trial Radar · NCT07789483
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,180
Planned (sponsor's estimate)
Start
Nov 23, 2027
Primary completion
Jul 11, 2030
Study completion Jul 11, 2030
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.
Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions
ALXN2220Drug
To be administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with TEAEsTime frame: Up to 24 months
Locations
195 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Irvine, California
Research Site
La Jolla, California
Research Site
Palo Alto, California
Research Site
San Francisco, California
Research Site
Aurora, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Weston, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Indianapolis, Indiana
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
New York, New York
Research Site
Stony Brook, New York
Research Site
Chapel Hill, North Carolina
Research Site
Durham, North Carolina
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Danville, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Greenville, South Carolina
Research Site
Memphis, Tennessee
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Research Site
Falls Church, Virginia
Research Site
Richmond, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Buenos Aires, Buenos Aires, Argentina
Research Site
CABA, Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
Research Site
Córdoba, Córdoba Province, Argentina
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.